WO2013084191A1 - Tableta orodispersable de sildenafil y método para preparar la misma - Google Patents
Tableta orodispersable de sildenafil y método para preparar la misma Download PDFInfo
- Publication number
- WO2013084191A1 WO2013084191A1 PCT/IB2012/057043 IB2012057043W WO2013084191A1 WO 2013084191 A1 WO2013084191 A1 WO 2013084191A1 IB 2012057043 W IB2012057043 W IB 2012057043W WO 2013084191 A1 WO2013084191 A1 WO 2013084191A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- further characterized
- amount
- tablet
- tablet according
- Prior art date
Links
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 title claims abstract description 109
- 229960003310 sildenafil Drugs 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title description 7
- 239000011230 binding agent Substances 0.000 claims abstract description 19
- 239000013543 active substance Substances 0.000 claims abstract description 14
- 239000003085 diluting agent Substances 0.000 claims abstract description 13
- 239000007884 disintegrant Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 32
- 239000008187 granular material Substances 0.000 claims description 25
- 235000003599 food sweetener Nutrition 0.000 claims description 14
- 239000003765 sweetening agent Substances 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229960000913 crospovidone Drugs 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- 239000004376 Sucralose Substances 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- -1 polyividone Polymers 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 4
- MCRNHLQVPJEMSQ-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] Chemical compound C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] MCRNHLQVPJEMSQ-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000004368 Modified starch Substances 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000000619 acesulfame-K Substances 0.000 claims description 3
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004384 Neotame Substances 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000008122 artificial sweetener Substances 0.000 claims description 2
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- 235000021096 natural sweeteners Nutrition 0.000 claims description 2
- 235000019412 neotame Nutrition 0.000 claims description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 2
- 108010070257 neotame Proteins 0.000 claims description 2
- 235000019204 saccharin Nutrition 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
- 229940081974 saccharin Drugs 0.000 claims description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 235000010358 acesulfame potassium Nutrition 0.000 claims 1
- 229960004998 acesulfame potassium Drugs 0.000 claims 1
- 239000008368 mint flavor Substances 0.000 claims 1
- 239000008371 vanilla flavor Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 72
- 229940112822 chewing gum Drugs 0.000 description 8
- 235000015218 chewing gum Nutrition 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 229940094720 viagra Drugs 0.000 description 7
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 150000003112 potassium compounds Chemical class 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229940103087 sildenafil 100 mg Drugs 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Definitions
- the present invention is related to a tablet comprising the active agent sildenafil that is useful for the treatment of erectile dysfunction and pulmonary arterial hypertension.
- PDE5 phosphodiesterase type 5
- sildenafil Due to its various applications, such as its use in the treatment of erectile dysfunction, the demand of the pharmaceutical agent sildenafil has registered a constant increase.
- Sildenafil is rapidly absorbed after oral administration, with absolute bioavailability approximately 40% (limits of 25 to 63%).
- the Maximum concentration of this free drug in plasma after a single oral dose of 100 mg is approximately 18 ng / mL or 38 nM.
- the elimination half-life of the compound is 3 to 4 hours after a dose in the range of 25 to 200 mg, increasing 30 minutes more if it is administered with food.
- the core comprises a phosphodiesterase type 5 inhibitor, such as sildenafil, as an active ingredient, a filler, a binder, a release control agent, a slider and a lubricant.
- the coating is selected from the group consisting of at least one pH-dependent coating film, a combination of two or more water insoluble polymers, a combination of at least one water swellable polymer and at least one polymer insoluble in water, a flexible but not water soluble coating, an inflatable coating and a water permeable coating. Again, to achieve the desired dissolution profile, a coated particle has to be prepared.
- the tablet comprises at least one polyol sweetening agent, at least one active ingredient and compressed particles of a chewing gum base material, wherein the polyol content is between 21 and 95% by weight of the tablet, and where the tablet is compressed at an ambient temperature below 25 ° C and a maximum relative humidity of 55%.
- the tablet of this document is only formulated to mask the taste of the active agent.
- Mexican patent application No. PA / a / 1999/004539 describes an orally disintegrable preparation comprising sildenafil as a free base and a pharmaceutically acceptable carrier and the method for preparing said preparation comprising combining and compressing a water-soluble, fusible binder, at least one excipient and sildenafil as a free base in a tablet, fusing said binder in said tablet and solidifying said binder.
- the binder is polyethylene glycol, a sugar ester, an ethoxylated fatty acid or an ethoxylated alcohol. According to the document, the only way to obtain the orally disintegrable preparation is by using the fusible binder.
- Mexican patent application No. MX / a / 2009/01 1973 describes a tablet formulation of low friability and rapid disintegration containing: a) 1 to 20% of an ethyl cellulose binder, b) from 2 to 15% of a disintegrant and c) sildenafil.
- the disintegrant is selected from the group consisting of cross-linked povidone, croscarmellose sodium (cross-linked sodium carboxymethyl cellulose), starch glycolate sodium, low-substituted hydroxypropyl cellulose and guar.
- the properties of the tablet are due to the use of ethyl cellulose as a binder.
- Mexican patent application No. MX / a / 2008/012299 describes an orally disintegrable tablet formulation comprising: a) sildenafil; b) compounds comprising calcium silicate that is coated with at least one carbohydrate; and c) at least one other excipient.
- the tablet has an optimal mechanical strength and a disintegration time of approximately 60 seconds in the oral cavity. In order to achieve this decay time, the use of the calcium silicate compound is necessary.
- the present invention solves the problems described above by means of an orodispersible tablet comprising sildenafil that dissolves in the oral cavity and is therefore suitable when swallowing a tablet, when there are no liquids available or when fluid intake causes problems. adjacent, such as vomit.
- a further objective of the present invention is to provide an orodispersible tablet comprising sildenafil and that eliminates the need to chew or fluid intake.
- a further objective of the present invention is to provide a process for the manufacture of an orodispersible tablet comprising the active agent sildenafil.
- Figures 1A and 1 B are graphs of plasma concentration vs. time of a tablet prepared according to the present invention, comparing it with reference tablets.
- Figure 2 shows a diagram of the process for preparing the tablet of the present application.
- the present application provides an orodispersible tablet comprising: a) Sildenafil or a pharmaceutically acceptable salt thereof;
- the tablet can comprise from 9 to 22% by weight of the active agent sildenafil or a pharmaceutically acceptable salt thereof, preferably from 1 to 14% by weight.
- the diluent can be selected from the group comprising mannitol, lactose, sucrose, inositol, dry starch and mixtures thereof.
- the diluent used for the manufacture of the tablet is mannitol.
- the diluent is present in an amount of 50 to 70% by weight of the tablet, preferably in an amount of 55 to 65% by weight.
- the disintegrant is selected from the group comprising microcrystalline cellulose, modified starch, polividone, crospovidone, and mixtures thereof. Due to its particular characteristics, the use of crospovidone as a disintegrant is preferred for the preparation of the tablet of the present invention.
- the amount of this ingredient used is 5 to 18% by weight of the tablet.
- the disintegrant is used in an amount of 13 to 17% by weight of the tablet.
- the binder used for the preparation of the tablet of the present invention can be selected from the group comprising microcrystalline cellulose, microfine cellulose, spray dried lactose, modified starch, gum arabic, gelatin, glucose, polyvinyl, starch, sucrose, and mixtures of the same.
- the binder used to prepare the tablet of the invention is polyvinyl.
- the binder is present in an amount of 2 to 6% by weight, and more preferably in an amount of 3 to 5% by weight.
- the tablet of the present invention may contain additional additives that aid in a suitable formulation such as lubricants, glidants, sweeteners, flavorings and colorants.
- Lubricants are pharmaceutical adjuvants that increase the flow properties of the particles.
- This ingredient can be selected from the group comprising corn starch, talc and stearyl sodium fumarate. Stearyl sodium fumarate is preferred to prepare the tablet of the invention.
- the amount of this ingredient ranges from 1.5 to 3.5% by weight of the tablet, more preferably in an amount of 1 .7 to 2.2% by weight.
- the sliders improve the ability of the powder to flow and can be selected from the group comprising colloidal silicon dioxide, talc, stearates, etc.
- colloidal silicon dioxide is preferred.
- the slider may be present in an amount of 0.5 to 1.5% by weight of the tablet, and preferably in an amount of 0.7 to 1.2% by weight.
- Suitable sweeteners for use in the present invention may be selected from the group comprising natural sweeteners such as sucrose, fructose, etc., and artificial sweeteners such as saccharin, aspartame, sucralose, neotame and acesulfame K (potassium acesulfame) .
- Sucralose is preferred as the sweetener of the tablet of the invention.
- the sweetener is added in an amount of 0.5 to 4.0% by weight of the tablet, and more preferably in an amount of 0.7 to 2.0% by weight of the tablet.
- flavoring agent is also recommended.
- Preferred flavors are mint, vanilla, strawberry, etc.
- the preferred flavoring is mint. This ingredient may be added in an amount of 2 to 8% by weight of the tablet, and more preferably in an amount of 3 to 6% by weight of the tablet.
- dyes can be used to improve the appearance of the tablet.
- This ingredient can be added in an amount of 0.01 to 0.05% by weight of the tablet. Preferably in an amount of 0.02% to 0.04% by weight.
- the tablet comprises: a) from 1 to 14% by weight of the active agent sildenafil or a pharmaceutically acceptable salt thereof, b) from 55 to 65% by weight of mannitol, c) from 13 to 17% by weight of crospovidone, d) from 3 to 5% by weight of polyvinyl and e) from 8 to 12% by weight of one or more pharmaceutically acceptable additives.
- the method for preparing the tablet of the present invention is illustrated in Figure 2 and comprises the steps of:
- step b) moisten the mixture from step a) with water;
- the tablet illustrated in Table 1 above was prepared by mixing in a Diosna kit the active agent sildenafil (in the form of citrate salt), a portion of the mannitol, a portion of the sucralose and the polycloneone binding agent. The resulting mixture is moistened with water. The wetted mixture is then granulated, dried in a fluidized bed and sifted equipment. Next, the granulate is mixed with the rest of the mannitol, the rest of the sucralose, the crospovidone, the mint flavoring agent and the blue dye No. 2 to form a second granulate. Next, the second granulate is mixed with colloidal silicon dioxide, to subsequently add to the mixture the sodium stearyl fumarate to form a third granulate. The latter granulate is evaluated with respect to its rheometry and morphology.
- the active agent sildenafil in the form of citrate salt
- a portion of the mannitol a portion of the su
- Rheometry is studied with a Power Rheometer FT4 device.
- the parameters evaluated are the following:
- G stability index that should be in the range of 0.800 to 1200, preferably 0.905 to 1,000
- H index of degree of fluidity that should be on the scale of 1.10 to 1.50, preferably 1.20 to 1.40
- I Stability energy that should be in the range of 3.0 to 6.0 mJ / g, preferably 4.0 to 5.5 mJ / g.
- the morphological characteristics of the third granulate are studied using a Morphologi G3 device.
- the parameters evaluated are:
- Circularity D (5.0] that should be on the scale of 0.750 to 1,000, preferably 0.850 to 0.900;
- Diameter D [n, 0.5] that should be in the range of 8.5 to 11.5 ⁇ , preferably 9.4 to 10.6 ⁇ ;
- the last step of the process is the compression of the third granulate to obtain the desired tablet.
- the Viagra® 100 mg tablet was used as a reference to demonstrate that the rapidity of sildenafil absorption in the test tablet did not have levels as high as those of the secondary reference (sildenafil 100 mg) and to verify that adverse events of the test tablet would not exceed those of the secondary reference tablet.
- the volunteers prior to fasting and the assigned sequence, received a single dose of the test tablet or reference tablets orally.
- the two reference tablets (Viagra® 50 mg and Viagra® 100 were administered by swallowing (with 250 ml of water), while the test tablet was allowed to dissolve in the oral cavity. 15 samples were taken to determine the plasma profile This same administration scheme was repeated in a second and third period
- the plasma quantification of sildenafil was performed by mass spectrometry (LC-MS-MS) on a high performance liquid chromatograph, model 1200 Agilent brand and a Mass spectrometer, model G64410B brand Agilent.
- Figure 1A shows a graph representing the plasma concentration (ng / mL) of sildenafil at the time of the three tablets evaluated.
- Figure 1 B shows only the plasma concentrations obtained for the Viagra® tablet with 50 mg of sildenafil and the orodispersible test tablet with 50 mg of the active agent.
- the orodispersible test tablet of the present invention has a pharmacokinetic behavior that is comparable to that of the Viagra® tablet with 50 mg of sildenafil.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2011013159A MX366768B (es) | 2011-12-08 | 2011-12-08 | Tableta orodispersable de sildenafil y metodo para preparar la misma. |
MXMX/A/2011/013159 | 2011-12-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013084191A1 true WO2013084191A1 (es) | 2013-06-13 |
WO2013084191A9 WO2013084191A9 (es) | 2013-08-15 |
Family
ID=48573651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/057043 WO2013084191A1 (es) | 2011-12-08 | 2012-12-06 | Tableta orodispersable de sildenafil y método para preparar la misma |
Country Status (5)
Country | Link |
---|---|
CL (1) | CL2014001487A1 (es) |
CO (1) | CO7091173A2 (es) |
GT (1) | GT201400108A (es) |
MX (1) | MX366768B (es) |
WO (1) | WO2013084191A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104546779A (zh) * | 2013-10-14 | 2015-04-29 | 深圳海王药业有限公司 | 高药物荷载的枸橼酸西地那非片剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0960621A2 (en) * | 1998-05-15 | 1999-12-01 | Pfizer Inc. | Pharmaceutical formulations comprising sildenafil |
EP1120120A1 (en) * | 1998-10-05 | 2001-08-01 | Eisai Co., Ltd. | Tablets immediately disintegrating in the oral cavity |
WO2011030351A2 (en) * | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Taste - masked pharmaceutical compositions |
-
2011
- 2011-12-08 MX MX2011013159A patent/MX366768B/es active IP Right Grant
-
2012
- 2012-12-06 WO PCT/IB2012/057043 patent/WO2013084191A1/es active Application Filing
-
2014
- 2014-06-06 CL CL2014001487A patent/CL2014001487A1/es unknown
- 2014-06-06 GT GT201400108A patent/GT201400108A/es unknown
- 2014-06-06 CO CO14122562A patent/CO7091173A2/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0960621A2 (en) * | 1998-05-15 | 1999-12-01 | Pfizer Inc. | Pharmaceutical formulations comprising sildenafil |
EP1120120A1 (en) * | 1998-10-05 | 2001-08-01 | Eisai Co., Ltd. | Tablets immediately disintegrating in the oral cavity |
WO2011030351A2 (en) * | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Taste - masked pharmaceutical compositions |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104546779A (zh) * | 2013-10-14 | 2015-04-29 | 深圳海王药业有限公司 | 高药物荷载的枸橼酸西地那非片剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
MX366768B (es) | 2019-07-17 |
CL2014001487A1 (es) | 2015-02-13 |
CO7091173A2 (es) | 2014-10-21 |
GT201400108A (es) | 2016-04-15 |
WO2013084191A9 (es) | 2013-08-15 |
MX2011013159A (es) | 2013-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2203495T3 (es) | Preparado farmaceutico de levodopa/carbidopa/entacapona. | |
ES2272082T3 (es) | Formulaciones farmaceuticas de liberacion controlada que contienen un inhibidor de pde-5 de gmpc. | |
ES2680638T3 (es) | Gránulos efervescentes de ácido gamma-hidroxibutírico | |
ES2167921T5 (es) | Comprimido multiparticulado perfeccionado de disgregación rápida | |
ES2537063T3 (es) | Composición farmacéutica mejorada que contiene un antagonista de dihidropiridina del canal de calcio y método para preparación de la misma | |
JP6067892B2 (ja) | 安定性を増強した新規な液体組成物 | |
RU2184570C2 (ru) | Препараты для орального введения | |
ES2624585T3 (es) | Sistema de suministro de compuesto terapéutico oral | |
ES2400774T3 (es) | Tableta que se disgrega rápidamente en la cavidad oral y método para producción de la misma | |
ES2612331T3 (es) | Composiciones farmacéuticas | |
EP2698145B1 (en) | Pharmaceutical Formulations comprising dapoxetine and a PDE5 inhibitor | |
ES2549224T3 (es) | Formulaciones orales de película que comprenden dapoxetina y tadalafilo | |
US20070082048A1 (en) | Sleep aid formulations | |
ES2912897T3 (es) | Formulaciones de diclofenaco y métodos de uso | |
ES2811110T3 (es) | Composición farmacéutica capaz de la incorporación de Lenalidomida en diversas modificaciones cristalinas | |
KR102239291B1 (ko) | 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제 | |
JP5337430B2 (ja) | 口腔内速崩壊錠 | |
WO2013024373A1 (en) | Pharmaceutical composition comprising cefuroxime | |
US20110028480A1 (en) | Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors | |
US20110257159A1 (en) | Orally disintegrating tablet formulations of mirtazapine and process for preparing the same | |
WO2013084191A1 (es) | Tableta orodispersable de sildenafil y método para preparar la misma | |
WO2013172297A1 (ja) | 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有製剤 | |
PL206248B1 (pl) | Rozpadająca się w ustach lub dyspergowalna tabletka oraz sposób jej wytwarzania | |
PT1646373E (pt) | Composição farmacêutica orodispersível de um composto antitrombótico | |
ES2784251T3 (es) | Formulaciones de disgregación por vía oral de tadalafilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12856434 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014001487 Country of ref document: CL Ref document number: 14122562 Country of ref document: CO |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12856434 Country of ref document: EP Kind code of ref document: A1 |